As more patients succeed on GLP-1 therapy, conversations about tapering these medications are becoming increasingly common in metabolic care. When patients reach meaningful goals in weight reduction, A1C improvement, or cardiometabolic risk, clinicians naturally begin asking what comes next. Is it safe to stop treatment? More importantly, can progress be …
Read More »GLP-1s and Food Noise: Helping Patients Understand Hunger, Cravings, and Control
Patients taking GLP-1 receptor agonists often describe a surprising change: the “volume” of food thoughts seems to turn down. This experience, often described as a reduction in food noise with GLP-1 therapy, reflects measurable neuroendocrine shifts in appetite regulation and reward signaling. For clinicians, understanding and explaining this phenomenon is …
Read More »GLP-1s in Young Adults: Rethinking Metabolic Risk and Early Intervention
For years, GLP-1 receptor agonists have been associated with older adults who already have type 2 diabetes or established cardiovascular disease. However, metabolic dysfunction does not suddenly appear at age 60. In fact, obesity, insulin resistance, and prediabetes often begin decades earlier. That is why conversations around GLP-1 therapy in …
Read More »Social Determinants First: Using CKM and SDOH to Sequence Diabetes Therapies in 2026
A patient’s A1C can look acceptable on paper while everything else is quietly heading in the wrong direction. Cardiovascular risk is rising, kidney function is slipping, and the patient keeps missing follow-up visits because of cost, transportation, or work constraints. Most clinicians have seen this scenario play out, even when …
Read More »AI for Diabetes in the Community: Bringing Decision Support Beyond the Specialty Clinic
A missed diagnosis, a delayed follow-up, or a rushed primary care visit can quietly shape the course of diabetes for years. For many patients, especially those outside specialty clinics, these small gaps add up. The challenge is not a lack of clinical knowledge, but a lack of timely support where …
Read More »Diabetes Care in the GLP-1 Era: Re-Designing Visits When One Drug Does So Much
GLP-1 receptor agonists have changed diabetes care faster than almost any therapy in recent history. In many ways, one medication now touches glucose control, weight loss, cardiovascular risk, and even liver health. However, while outcomes have evolved, the typical clinic visit has stayed the same. As a result, clinicians often …
Read More »GLP-1s and Serious Mental Illness: Tackling Antipsychotic-Associated Weight Gain
For many patients, antipsychotic medications are life-changing, even life-saving. Yet the same treatments that stabilize mood and thought can quietly drive weight gain, insulin resistance, and rising cardiometabolic risk. Over time, this unintended consequence places patients with serious mental illness at a much higher risk for obesity, type 2 diabetes, …
Read More »GLP-1s in the Hospital: Should We Hold, Continue, or Start Inpatient?
A patient is scheduled for surgery tomorrow morning. During medication reconciliation, you notice they took their weekly semaglutide dose two days ago. They feel fine, but anesthesia is concerned about aspiration risk. Meanwhile, glucose levels are creeping up. Do you hold the medication, continue it, or change course entirely? Situations …
Read More »GLP-1s and Lean Mass: Preserving Muscle and Strength During Rapid Weight Loss
The scale is moving fast, clothes are fitting better, and blood sugar numbers are improving. For many people using GLP-1 medications, weight loss can feel almost effortless at first. Yet beneath those encouraging changes, another question often emerges: is muscle being lost along with fat? For individuals focused on long-term …
Read More »GLP-1s and Dermatologic Disease: From Psoriasis to Hidradenitis—Signal or Noise?
A patient returns for follow-up after starting a GLP-1 receptor agonist and mentions something unexpected. Their blood glucose is improved, weight is down, and their psoriasis seems quieter. Another patient reports fewer hidradenitis flares. These anecdotes are becoming more common, raising a practical question for clinicians. Are GLP-1 therapies influencing …
Read More »
Diabetes In Control. A free weekly diabetes newsletter for Medical Professionals. News and information for Medical Professionals.